TCIM
ENTA icon

TIAA CREF Investment Management’s Enanta Pharmaceuticals ENTA Stock Holding History

TIAA CREF Investment Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$3.11M Sell
32,544
-444
-1% -$39.8K ﹤0.01% 1744
2018
Q4 		$2.34M Sell
32,988
-1,466
-4% -$112K ﹤0.01% 1862
2018
Q3 		$2.94M Sell
34,454
-2,806
-8% -$281K ﹤0.01% 1928
2018
Q2 		$4.32M Sell
37,260
-1,457
-4% -$145K ﹤0.01% 1709
2018
Q1 		$3.13M Buy
38,717
+476
+1% +$36.6K ﹤0.01% 1853
2017
Q4 		$2.24M Sell
38,241
-2,843
-7% -$142K ﹤0.01% 2074
2017
Q3 		$1.92M Sell
41,084
-1,867
-4% -$75K ﹤0.01% 2189
2017
Q2 		$1.54M Sell
42,951
-382
-0.9% -$12.2K ﹤0.01% 2337
2017
Q1 		$1.33M Sell
43,333
-4,258
-9% -$133K ﹤0.01% 2366
2016
Q4 		$1.59M Sell
47,591
-15,724
-25% -$451K ﹤0.01% 2309
2016
Q3 		$1.69K Sell
63,315
-26,309
-29% -$611K ﹤0.01% 2264
2016
Q2 		$1.98M Buy
89,624
+776
+0.9% +$20.3K ﹤0.01% 2134
2016
Q1 		$2.61M Buy
88,848
+30,840
+53% +$859K ﹤0.01% 1928
2015
Q4 		$1.92M Sell
58,008
-9,589
-14% -$313K ﹤0.01% 2183
2015
Q3 		$2.44M Sell
67,597
-1,399
-2% -$60.1K ﹤0.01% 2024
2015
Q2 		$3.1M Buy
68,996
+10,905
+19% +$424K ﹤0.01% 2016
2015
Q1 		$1.78M Sell
58,091
-788
-1% -$30.7K ﹤0.01% 2290
2014
Q4 		$2.99M Sell
58,879
-1,006
-2% -$45K ﹤0.01% 1977
2014
Q3 		$2.37M Sell
59,885
-14,877
-20% -$593K ﹤0.01% 2116
2014
Q2 		$3.22M Buy
74,762
+2,216
+3% +$84.5K ﹤0.01% 1998
2014
Q1 		$2.9M Buy
72,546
+36,976
+104% +$1.34M ﹤0.01% 2013
2013
Q4 		$970K Buy
35,570
+20,755
+140% +$503K ﹤0.01% 2692
2013
Q3 		$340K Buy
14,815
+463
+3% +$8.85K ﹤0.01% 3015
2013
Q2 		$254K Buy
+14,352
New +$280K ﹤0.01% 3035

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

TIAA CREF Investment Management's ENTA Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Enanta Pharmaceuticals (ENTA) stake by 1.3% in Q1 2019, selling an estimated $39.8K and leaving 32,544 shares worth $3.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1744.

TIAA CREF Investment Management first reported a position in ENTA in Q2 2013 and has held it in 24 quarters since. The position peaked at $4.32M in Q2 2018. 195 funds tracked by Wall St. Rank hold ENTA as of Q1 2019.

  • TIAA CREF Investment Management held 32,544 shares of Enanta Pharmaceuticals worth $3.11M as of Q1 2019.
  • TIAA CREF Investment Management sold 444 Enanta Pharmaceuticals shares in Q1 2019, an estimated $39.8K.
  • Enanta Pharmaceuticals made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1744 holding.
  • TIAA CREF Investment Management first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Enanta Pharmaceuticals position peaked at $4.32M in Q2 2018.
  • 195 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.